Short-term bullish outlook for Caplin Point Laboratories with potential rise to ₹1,750; traders advised to go long at ₹1,640.

Stock to buy today: Caplin Point Laboratories (₹1,640.05): BUY

Caplin Steriles (Caplin), a subsidiary company of Caplin Point Laboratories, has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ephedrine Sulfate injection USP, 50 mg/mL Single Dose vial, a generic therapeutic equivalent version of the Reference Listed Drug (RLD) AKOVAZ, from Exela Pharma Sciences LLC.

Corporate

Caplin Steriles receives USFDA approval for Ephedrine Sulfate injection

Caplin Point Laboratories said that its subsidiary Caplin Steriles has been granted final approval from the United States Food and Drug Administration (US FDA) for its abbreviated new drug application (ANDA) for Ephedrine Sulfate Injection.

Spotlight

Caplin Point Labs subsidiary gets US FDA nod for Ephedrine Sulfate Injection

Caplin Point Laboratories Ltd, Gravita India Ltd, AAVAS Financiers Ltd and Shivalik Bimetal Controls Ltd are among the other losers in the BSE’s ‘A’ group today, 13 June 2024.

Sanofi India Ltd leads losers in ‘A’ group

#4QWithCNBCTV18 | Caplin Point Lab posts a steady set of Q4 earnings. COO, Vivek Partheeban tells Prashant Nair & Reema Tendulkar that there is pricing pressure overall, but do not see much impact. Adds growth momentum to continue and expect healthy orderbook for US.

#caplinpointlab #caplinpoint #cnbctv18 #businessnews #businessnewstoday #businessnewsinenglish #sharemarkettoday        

🔴CNBC TV18 LIVE TV: https://youtube.com/live/P857H4ej-MQ
SUBSCRIBE to our Channel: https://bit.ly/3nvEcxf
---------------------------------------------------------------------------------------------------------------------
                               👑 Check Out Top CNBC TV18 Playlist Videos: 

🔹CNBC TV18 Digital Podcast: https://www.youtube.com/playlist?list=PLjq9mRS1PfGCUcGVQvYyDQ6VVHoo3ZDKJ

🔹CNBC TV18 Market Cafe: https://www.youtube.com/playlist?list=PLjq9mRS1PfGDANftdnJchuL-WPpSv5rmH

🔹CNBC TV18 Digital: https://www.youtube.com/playlist?list=PLjq9mRS1PfGDLhtM8FzErPcjmJRQ4I5cZ

🔹CNBC TV18 Weekend Special: https://www.youtube.com/playlist?list=PLjq9mRS1PfGBHEa5NnoKuUsX5GwxEGuri

🔹CNBC TV18 Next-Gen: https://www.youtube.com/playlist?list=PLjq9mRS1PfGA6roe9q3J9fq_gBIDjX2w7

🔹Overdrive Show: https://www.youtube.com/playlist?list=PLjq9mRS1PfGCnSVjfbWfNCJLrv-CqfGmH

🔹CNBC TV18 Newsreels: https://www.youtube.com/playlist?list=PLjq9mRS1PfGCmABWWQRX4NqGLCtScwqex

🔹Young Turks: https://www.youtube.com/playlist?list=PLjq9mRS1PfGBZaN1e38X2ZmevnU1e1NJs

🔹Startup Streets: https://www.youtube.com/playlist?list=PLjq9mRS1PfGD3CzrtMr_VJRbIly6sfyFI

------------------------------------------------------------------------------------
You can also connect with CNBC-TV18 News Online
Catch the latest news: https://bit.ly/2YbpXBM

Follow CNBC-TV18 round the clock: https://www.cnbctv18.com/live-tv/

Stay updated with all the market action in real time: https://www.cnbctv18.com/market-live/

You can also stay updated with all the latest news on-the-go with CNBC-TV18 Minis: https://www.cnbctv18.com/minis/

Like us on Facebook: https://www.facebook.com/cnbctv18india/
Follow us on Twitter: https://twitter.com/CNBCTV18News
Follow us on Instagram: https://www.instagram.com/cnbctv18india/
Catch us on: Linkedin: https://in.linkedin.com/company/cnbc-tv18
n18oc_business

Don't See Much Impact Of Pricing Pressure. Expect Healthy Orderbook In US: Caplin Point | CNBC TV18

Chennai-based Caplin Point Laboratories has allocated ₹500-550 crore for capex, incl. expanding existing capacities, additional manufacturing sites & backward integration. It has completed expansion activities in Q4FY23 & ongoing projects in TN, AP & Puducherry. Q1FY24 saw 21% y-o-y growth in net pr…

Caplin Point working on ₹550-crore capex expansion

Caplin Point Labs earns spot on Forbes Asia’s “200 Best Under a Billion” list for 2023. Evaluating 20,000+ Asia-Pacific companies, the list honors those with annual sales under $1B. Criteria included debt mgmt, sales growth, EPS performance, and ROE. Shares down 3.25% to ₹1,028.

Caplin Point secures spot on Forbes list of ‘200 Best Under a Billion’

Caplin Point Laboratories has reported a 21 per cent year-on-year growth in its consolidated net profit for the first quarter at ₹104 crore

Caplin Point Q1 net profit jumps 21% to ₹104 crore

Caplin Point Labs’ subsidiary Caplin Steriles Ltd has approved setting up of a wholly-owned US-based subsidiary, Caplin Steriles USA Inc. It will have an initial share capital of $5,00,000 and cater to regulated markets like US & Europe for injectable & ophthalmic products. Caplin Steriles USA Inc w…

Caplin Point to set up step-down subsidiary to focus on US market

Caplin Point said the capex outlay includes expansion of Phase 2 & 3 projects of Caplin Steriles

Caplin Point chalks ₹350 crore capex for expansion

Shares of Caplin Point were trading at ₹754.60 apiece on NSE against the previous day’s closing price of ₹747.60 per share.

USFDA issues four observations on Caplin Point subsidiary’s injectable unit

Price return has been average, nothing exciting

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced and in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Not a good time to consider, stock is in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Caplin Point Laboratories Limited is a pharmaceutical company. The Company's product segments include Antibiotics, Non-steroidal anti-inflammatory drugs (NSAIDS), Ophthalmics, Pain Management and Anti-ulcers.